Myriad Genetics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $16.04
- Today's High:
- $16.47
- Open Price:
- $16.28
- 52W Low:
- $13.92
- 52W High:
- $24.21
- Prev. Close:
- $16.31
- Volume:
- 299583
Company Statistics
- Market Cap.:
- $1.34 billion
- Book Value:
- 8.977
- Revenue TTM:
- $698.90 million
- Operating Margin TTM:
- -25.67%
- Gross Profit TTM:
- $476.40 million
- Profit Margin:
- -35.51%
- Return on Assets TTM:
- -9.35%
- Return on Equity TTM:
- -29.5%
Company Profile
Myriad Genetics Inc had its IPO on 1995-10-05 under the ticker symbol MYGN.
The company operates in the Healthcare sector and Diagnostics & Research industry. Myriad Genetics Inc has a staff strength of 2,600 employees.
Stock update
Shares of Myriad Genetics Inc opened at $16.28 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $16.04 - $16.47, and closed at $16.32.
This is a +0.06% increase from the previous day's closing price.
A total volume of 299,583 shares were traded at the close of the day’s session.
In the last one week, shares of Myriad Genetics Inc have slipped by -9.43%.
Myriad Genetics Inc's Key Ratios
Myriad Genetics Inc has a market cap of $1.34 billion, indicating a price to book ratio of 1.6656 and a price to sales ratio of 2.1502.
In the last 12-months Myriad Genetics Inc’s revenue was $698.90 million with a gross profit of $476.40 million and an EBITDA of $-119900000. The EBITDA ratio measures Myriad Genetics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Myriad Genetics Inc’s operating margin was -25.67% while its return on assets stood at -9.35% with a return of equity of -29.5%.
In Q2, Myriad Genetics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2.3%.
Myriad Genetics Inc’s PE and PEG Ratio
- Forward PE
- 40.9836
- Trailing PE
- 0
- PEG
- 1.1102
Its diluted EPS in the last 12-months stands at $-2.97 per share while it has a forward price to earnings multiple of 40.9836 and a PEG multiple of 1.1102. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Myriad Genetics Inc’s profitability.
Myriad Genetics Inc stock is trading at a EV to sales ratio of 2.2237 and a EV to EBITDA ratio of -19.1258. Its price to sales ratio in the trailing 12-months stood at 2.1502.
Myriad Genetics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.19 billion
- Total Liabilities
- $221.10 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $18.80 million
- Dividend Payout Ratio
- 0%
Myriad Genetics Inc ended 2024 with $1.19 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.19 billion while shareholder equity stood at $735.20 million.
Myriad Genetics Inc ended 2024 with $0 in deferred long-term liabilities, $221.10 million in other current liabilities, 800000.00 in common stock, $-537000000.00 in retained earnings and $287.20 million in goodwill. Its cash balance stood at $102.80 million and cash and short-term investments were $121.60 million. The company’s total short-term debt was $17,000,000 while long-term debt stood at $38.40 million.
Myriad Genetics Inc’s total current assets stands at $294.30 million while long-term investments were $6.20 million and short-term investments were $18.80 million. Its net receivables were $111.70 million compared to accounts payable of $39.80 million and inventory worth $22.50 million.
In 2024, Myriad Genetics Inc's operating cash flow was $0 while its capital expenditure stood at $18.80 million.
Comparatively, Myriad Genetics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $16.32
- 52-Week High
- $24.21
- 52-Week Low
- $13.92
- Analyst Target Price
- $21.72
Myriad Genetics Inc stock is currently trading at $16.32 per share. It touched a 52-week high of $24.21 and a 52-week low of $24.21. Analysts tracking the stock have a 12-month average target price of $21.72.
Its 50-day moving average was $19.66 and 200-day moving average was $20.29 The short ratio stood at 7.67 indicating a short percent outstanding of 0%.
Around 222.5% of the company’s stock are held by insiders while 10301.1% are held by institutions.
Frequently Asked Questions About Myriad Genetics Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women’s and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.